Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
126 hedge funds and large institutions have $1B invested in Five Prime Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 12 closing their positions.
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
36% more capital invested
Capital invested by funds: $737M → $1B (+$264M)
2% more funds holding
Funds holding: 123 → 126 (+3)
12% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 42
12% less call options, than puts
Call options by funds: $6.62M | Put options by funds: $7.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$31.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$4.99M |
| 3 |
Millennium Management
New York
|
+$4.38M |
| 4 |
Axa
Paris,
France
|
+$4.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$11.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$10.9M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$8.6M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.61M |
| 5 |
Goldman Sachs
New York
|
-$4.52M |
FPRX Hedge Fund Activity: Q3 2017 in Review
126 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2017, worth a combined $1B — up 36% from $737M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new FPRX positions and 12 closed out — a net gain of 5 holders — while 37 added to existing stakes and 42 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $31.7M. The largest seller was Renaissance Technologies, cutting an estimated $11.3M.
- 126 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2017, up from 123 in Q2 2017.
- Funds reported $1B of Five Prime Therapeutics, Inc. stock for Q3 2017, up 36% quarter-over-quarter.
- 17 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2017 and 12 closed out, a net change of +5 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2017 was HealthCor Management, an estimated $31.7M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2017 was Renaissance Technologies, an estimated $11.3M sold.
Based on aggregated 13F filings for Q3 2017.